AstraZeneca Asks FDA To Block Generic Crestor Until 2023


AstraZeneca is currently only dealing with a single generic competitor for its blockbuster drug Crestor. There is a flood of generic competition looking to enter the market, and AstraZeneca has filed a citizen petition with the FDA in a long shot bid to limit competitors. AstraZeneca is arguing that since the FDA granted Crestor a new indication in May of this year, exclusivity should last until May of 2023. The petition is considered unlikely to be successful.

Read the source article at FiercePharma

About the Author

Related Posts

Leave a Reply